The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance

Journal of Cardiovascular Magnetic Resonance

Volumn 14, Issue 1, 2012, Pages

  Noureldin, Radwa A ^a   Liu, Songtao ^a,b   Nacif, Marcelo S ^a   Judge, Daniel P ^c   Halushka, Marc K ^c   Abraham, Theodore P ^c   Ho, Carolyn ^d   Bluemke, David A ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM; DIAGNOSTIC AGENT;

CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE EXPRESSION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; DISEASE COURSE; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; FIBROSIS; GENETIC PREDISPOSITION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; SUDDEN DEATH;

CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; CONTRAST MEDIA; DEATH, SUDDEN, CARDIAC; DISEASE PROGRESSION; FIBROSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; VENTRICULAR FUNCTION, LEFT;

EID: 84860581944     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-14-17     Document Type: Review

References (119)

1. Hypertrophic cardiomyopathy: a systematic review. Maron BJ, JAMA 2002 287 1308 1320 10.1001/jama.287.10.1308 11886323 (Pubitemid 34250486)
2. Cardiovascular magnetic resonance in the evaluation of hypertrophic and infiltrative cardiomyopathies. O'Hanlon R, Pennell DJ, Heart Fail Clin 2009 5 369 387 vi 10.1016/j.hfc.2009.02.003 19564014
3. Genetic evaluation of familial cardiomyopathy. Judge DP, Johnson NM, J Cardiovasc Transl Res 2008 1 144 154 10.1007/s12265-008-9025-1 20559909
4. Penetrance of familial hypertrophic cardiomyopathy. Charron P, Carrier L, Dubourg O, Tesson F, Desnos M, Richard P, Bonne G, Guicheney P, Hainque B, Bouhour JB, et al. Genet Couns 1997 8 107 114 9219008 (Pubitemid 27273731)
5. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, Circulation 2006 113 1807 1816 10.1161/CIRCULATIONAHA.106. 174287 16567565 (Pubitemid 43958474)
6. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. Germans T, Wilde AA, Dijkmans PA, Chai W, Kamp O, Pinto YM, van Rossum AC, J Am Coll Cardiol 2006 48 2518 2523 10.1016/j.jacc.2006.08.036 17174192 (Pubitemid 44881223)
7. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED, J Am Coll Cardiol 2003 42 1687 1713 10.1016/S0735-1097(03)00941-0 14607462 (Pubitemid 37383745)
8. Hypertrophic cardiomyopathy. Towbin JA, Pacing Clin Electrophysiol 2009 32 Suppl 2 23 31 19602159
9. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ, J Am Coll Cardiol 2000 36 2212 2218 10.1016/S0735-1097(00) 01003-2 11127463
10. The management of hypertrophic cardiomyopathy. Spirito P, Seidman CE, McKenna WJ, Maron BJ, N Engl J Med 1997 336 775 785 10.1056/NEJM199703133361107 9052657 (Pubitemid 27113973)
11. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kuhl U, Maisch B, McKenna WJ, et al. Eur Heart J 2008 29 270 276 17916581
12. Evaluation of pathological criteria for diagnosis of hypertrophic cardiomyopathy. Rose AG, Histopathology 1984 8 395 406 10.1111/j.1365-2559.1984. tb02352.x 6539746 (Pubitemid 14107612)
13. Regional thicknesses and thickening of compacted and trabeculated myocardial layers of the normal left ventricle studied by cardiovascular magnetic resonance. Dawson DK, Maceira AM, Raj VJ, Graham C, Pennell DJ, Kilner PJ, Circ Cardiovasc Imaging 2011 4 139 146 10.1161/CIRCIMAGING.110.960229 21193690
14. Asymmetrical hypertrophy of the heart in young adults. Teare D, Br Heart J 1958 20 1 8 10.1136/hrt.20.1.1 13499764
15. The pathology of hypertrophic cardiomyopathy. Hughes SE, Histopathology 2004 44 412 427 10.1111/j.1365-2559.2004.01835.x 15139989 (Pubitemid 38725670)
16. Hypertrophic cardiomyopathy-pathology and pathogenesis. Davies MJ, McKenna WJ, Histopathology 1995 26 493 500 10.1111/j.1365-2559.1995.tb00267.x 7665141
17. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Klues HG, Maron BJ, Dollar AL, Roberts WC, Circulation 1992 85 1651 1660 1572023
18. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Maron BJ, Roberts WC, Circulation 1979 59 689 706 570464 (Pubitemid 9154961)
19. The current status of myocardial disarray in hypertrophic cardiomyopathy. Davies MJ, Br Heart J 1984 51 361 363 10.1136/hrt.51.4.361 6538431 (Pubitemid 14174152)
20. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. Factor SM, Butany J, Sole MJ, Wigle ED, Williams WC, Rojkind M, J Am Coll Cardiol 1991 17 1343 1351 10.1016/S0735-1097(10)80145-7 2016452
21. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. Maron BJ, Wolfson JK, Epstein SE, Roberts WC, J Am Coll Cardiol 1986 8 545 557 10.1016/S0735-1097(86)80181-4 3745699 (Pubitemid 16048006)
22. Luminal narrowing of coronary capillaries in human hypertrophic hearts: an ultrastructural morphometrical study using endomyocardial biopsy specimens. Takemura G, Takatsu Y, Fujiwara H, Heart 1998 79 78 85 9505925 (Pubitemid 28179069)
23. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ, Circulation 2005 112 855 861 10.1161/CIRCULATIONAHA.104.507723 16087809 (Pubitemid 41170072)
24. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E, J Am Coll Cardiol 2009 54 220 228 10.1016/j.jacc.2009.05.006 19589434
25. Hypertrophic cardiomyopathy. Elliott P, McKenna WJ, Lancet 2004 363 1881 1891 10.1016/S0140-6736(04)16358-7 15183628 (Pubitemid 38748646)
26. Magnetic Resonance Imaging of Hypertrophic Cardiomyopathy. Cannavale A, Ordovas KG, Higgins CB, J Thorac Imaging 2010
27. Cardiomyopathy: The diagnosis of hypertrophic cardiomyopathy. Wigle ED, Heart 2001 86 709 714 10.1136/heart.86.6.709 11711479 (Pubitemid 33086901)
28. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron BJ, Circulation 2011 124 40 47 10.1161/CIRCULATIONAHA.110.985812 21670234
29. MRI of hypertrophic cardiomyopathy: part I, MRI appearances. Hansen MW, Merchant N, AJR Am J Roentgenol 2007 189 1335 1343 10.2214/AJR.07.2286 18029869 (Pubitemid 350174792)
30. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, De Santis M, Quarta G, Nistri S, Cecchi F, et al. J Am Coll Cardiol 2008 52 559 566 10.1016/j.jacc.2008.04.047 18687251
31. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Seidman JG, Seidman C, Cell 2001 104 557 567 10.1016/S0092-8674(01)00242-2 11239412 (Pubitemid 32201950)
32. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Spirito P, Maron BJ, Bonow RO, Epstein SE, Am J Cardiol 1987 60 123 129 10.1016/0002-9149(87) 90998-2 3604925 (Pubitemid 17137391)
33. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. Shirani J, Pick R, Roberts WC, Maron BJ, J Am Coll Cardiol 2000 35 36 44 10.1016/S0735-1097(99)00492-1 10636256 (Pubitemid 30061256)
34. Apical hypertrophic cardiomyopathy: clinical, electrocardiographic, scintigraphic, echocardiographic, and magnetic resonance imaging findings of a case. Sperling RT, Parker JA, Manning WJ, Danias PG, J Cardiovasc Magn Reson 2002 4 291 295 10.1081/JCMR-120003956 12074145 (Pubitemid 34596291)
35. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Moon JC, Fisher NG, McKenna WJ, Pennell DJ, Heart 2004 90 645 649 10.1136/hrt.2003.014969 15145868 (Pubitemid 38668538)
36. Morphological onset and early diagnosis in apical hypertrophic cardiomyopathy: a long term analysis with nuclear magnetic resonance imaging. Suzuki J, Shimamoto R, Nishikawa J, Yamazaki T, Tsuji T, Nakamura F, Shin WS, Nakajima T, Toyo-Oka T, Ohotomo K, J Am Coll Cardiol 1999 33 146 151 10.1016/S0735-1097(98)00527-0 9935021 (Pubitemid 29064085)
37. Cardiac motion tracking using CINE harmonic phase (HARP) magnetic resonance imaging. Osman NF, Kerwin WS, McVeigh ER, Prince JL, Magn Reson Med 1999 42 1048 1060 10.1002/(SICI)1522-2594(199912)42:6<1048::AID-MRM9>3.0. CO;2-M 10571926
38. Focal hypertrophic cardiomyopathy simulating a mass: MR tagging for correct diagnosis. Bergey PD, Axel L, AJR Am J Roentgenol 2000 174 242 244 10628486 (Pubitemid 30030243)
39. Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. Lever HM, Karam RF, Currie PJ, Healy BP, Circulation 1989 79 580 589 10.1161/01.CIR.79.3.580 2917389 (Pubitemid 19087709)
40. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. Solomon SD, Wolff S, Watkins H, Ridker PM, Come P, McKenna WJ, Seidman CE, Lee RT, J Am Coll Cardiol 1993 22 498 505 10.1016/0735-1097(93)90055-6 8335820 (Pubitemid 23214563)
41. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. Ackerman MJ, VanDriest SL, Ommen SR, Will ML, Nishimura RA, Tajik AJ, Gersh BJ, J Am Coll Cardiol 2002 39 2042 2048 10.1016/S0735-1097(02)01900-9 12084606 (Pubitemid 34628288)
42. Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. Kokado H, Shimizu M, Yoshio H, Ino H, Okeie K, Emoto Y, Matsuyama T, Yamaguchi M, Yasuda T, Fujino N, et al. Circulation 2000 102 663 669 10931807 (Pubitemid 30640667)
43. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. Dhandapany PS, Sadayappan S, Xue Y, Powell GT, Rani DS, Nallari P, Rai TS, Khullar M, Soares P, Bahl A, et al. Nat Genet 2009 41 187 191 10.1038/ng.309 19151713
44. Gene mutations in apical hypertrophic cardiomyopathy. Arad M, Penas-Lado M, Monserrat L, Maron BJ, Sherrid M, Ho CY, Barr S, Karim A, Olson TM, Kamisago M, et al. Circulation 2005 112 2805 2811 10.1161/CIRCULATIONAHA.105.547448 16267253 (Pubitemid 41641675)
45. Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular non-compaction, and septal defects. Monserrat L, Hermida-Prieto M, Fernandez X, Rodriguez I, Dumont C, Cazon L, Cuesta MG, Gonzalez-Juanatey C, Peteiro J, Alvarez N, et al. Eur Heart J 2007 28 1953 1961 10.1093/eurheartj/ehm239 17611253 (Pubitemid 47579548)
46. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ, J Am Coll Cardiol 2004 44 1903 1910 10.1016/j.jacc.2004.07.045 15519027 (Pubitemid 39424094)
47. Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy. Ho CY, Lever HM, DeSanctis R, Farver CF, Seidman JG, Seidman CE, Circulation 2000 102 1950 1955 11034944
48. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Olivotto I, Girolami F, Ackerman MJ, Nistri S, Bos JM, Zachara E, Ommen SR, Theis JL, Vaubel RA, Re F, et al. Mayo Clin Proc 2008 83 630 638 18533079 (Pubitemid 351810562)
49. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. Girolami F, Ho CY, Semsarian C, Baldi M, Will ML, Baldini K, Torricelli F, Yeates L, Cecchi F, Ackerman MJ, Olivotto I, J Am Coll Cardiol 2010 55 1444 1453 10.1016/j.jacc.2009.11.062 20359594
50. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG, Prog Cardiovasc Dis 1985 28 1 83 10.1016/0033-0620(85) 90024-6 3160067 (Pubitemid 15237515)
51. The cardiomyopathies: an overview. Davies MJ, Heart 2000 83 469 474 10.1136/heart.83.4.469 10722553 (Pubitemid 30316769)
52. Sudden cardiac death in hypertrophic cardiomyopathy. Maron BJ, Fananapazir L, Circulation 1992 85 57 63 1728506
53. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ, N Engl J Med 2000 342 1778 1785 10.1056/NEJM200006153422403 10853000 (Pubitemid 30390237)
54. Cardiovascular magnetic resonance imaging: current and emerging applications. Lima JA, Desai MY, J Am Coll Cardiol 2004 44 1164 1171 10.1016/j.jacc.2004.06.033 15364314 (Pubitemid 39208868)
55. Expanding role of cardiovascular magnetic resonance in left and right ventricular diastolic function. Rathi VK, Biederman RW, Heart Fail Clin 2009 5 421 435, vii 10.1016/j.hfc.2009.02.005 19564017
56. Assessment of diastolic function by cardiac MRI. Lamb BPPHJ, Cardiovascular magnetic resonance imaging Totowa, NJ: Humana Press, CANNON CP, 2008 415 428
57. Myocardial tissue tagging with cardiovascular magnetic resonance. Shehata ML, Cheng S, Osman NF, Bluemke DA, Lima JA, J Cardiovasc Magn Reson 2009 11 55 10.1186/1532-429X-11-55 20025732
58. Assessment of left ventricular diastolic function in dilated cardiomyopathy with cine magnetic resonance imaging: effect of an angiotensin converting enzyme inhibitor, benazepril. Fujita N, Hartiala J, O'Sullivan M, Steiman D, Chatterjee K, Parmley WW, Higgins CB, Am Heart J 1993 125 171 178 10.1016/0002-8703(93)90071-G 8417514 (Pubitemid 23021640)
59. Relaxation in hypertrophic cardiomyopathy and hypertensive heart disease: relations between hypertrophy and diastolic function. De Marchi SF, Allemann Y, Seiler C, Heart 2000 83 678 684 10.1136/heart.83.6.678 10814629 (Pubitemid 30345972)
60. Effect of regional myocardial perfusion abnormalities on regional myocardial early diastolic function in patients with hypertrophic cardiomyopathy. Yamanari H, Kakishita M, Fujimoto Y, Hashimoto K, Kiyooka T, Katayama Y, Otsuka F, Emori T, Uchida S, Ohe T, Heart Vessels 1997 12 192 198 10.1007/BF02767047 9559969 (Pubitemid 28118721)
61. Relaxation and diastole of the heart. Brutsaert DL, Sys SU, Physiol Rev 1989 69 1228 1315 2678168 (Pubitemid 19255838)
62. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, Quinones MA, Roberts R, Marian AJ, Circulation 2001 104 128 130 11447072 (Pubitemid 32655824)
63. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, Seidman CE, Solomon SD, Circulation 2002 105 2992 2997 10.1161/01.CIR.0000019070.70491.6D 12081993 (Pubitemid 34693832)
64. Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Ho CY, Carlsen C, Thune JJ, Havndrup O, Bundgaard H, Farrohi F, Rivero J, Cirino AL, Andersen PS, Christiansen M, et al. Circ Cardiovasc Genet 2009 2 314 321 10.1161/ CIRCGENETICS.109.862128 20031602
65. Right ventricular function in patients after acute myocardial infarction assessed with phase contrast MR velocity mapping encoded in three directions. Kayser HW, van der Geest RJ, van der Wall EE, Duchateau C, de Roos A, J Magn Reson Imaging 2000 11 471 475 10.1002/(SICI)1522-2586(200005)11:5<471::AID- JMRI1>3.0.CO;2-D 10813855 (Pubitemid 30252832)
66. Regional differences in shape and load in normal and diseased hearts studied by three dimensional tagged magnetic resonance imaging. Petrank YF, Dong SJ, Tyberg J, Sideman S, Beyar R, Int J Card Imaging 1999 15 309 321 10.1023/A:1006132709895 10517381 (Pubitemid 29404769)
67. Cardiac rotation and relaxation in patients with aortic valve stenosis. Nagel E, Stuber M, Burkhard B, Fischer SE, Scheidegger MB, Boesiger P, Hess OM, Eur Heart J 2000 21 582 589 10.1053/euhj.1999.1736 10775013 (Pubitemid 30148323)
68. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, Lytle BW, Lever HM, Desai MY, J Am Coll Cardiol 2009 54 242 249 10.1016/j.jacc.2009.04.026 19589437
69. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H, J Am Coll Cardiol 2010 56 875 887 10.1016/j.jacc.2010.05.007 20667520
70. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS, J Am Coll Cardiol 2008 51 1369 1374 10.1016/j.jacc.2007.11.071 18387438 (Pubitemid 351443083)
71. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, Bonow RO, Judd RM, Kim RJ, J Am Coll Cardiol 2002 40 2156 2164 10.1016/S0735-1097(02)02602-5 12505229 (Pubitemid 36005903)
72. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ, J Am Coll Cardiol 2003 41 1561 1567 10.1016/S0735-1097(03)00189-X 12742298 (Pubitemid 36543376)
73. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, et al. J Am Coll Cardiol 2010 56 867 874 10.1016/j.jacc.2010.05.010 20688032
74. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, Petrou M, Pennell DJ, J Am Coll Cardiol 2004 43 2260 2264 10.1016/j.jacc.2004.03.035 15193690 (Pubitemid 38757595)
75. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. Ho CY, Lopez B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, Gonzalez A, Colan SD, Seidman JG, et al. N Engl J Med 2010 363 552 563 10.1056/NEJMoa1002659 20818890
76. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, Schulz-Menger J, J Am Coll Cardiol 2009 53 284 291 10.1016/j.jacc.2008.08.064 19147047
77. First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the alpha-tropomyosin gene. Sipola P, Lauerma K, Husso-Saastamoinen M, Kuikka JT, Vanninen E, Laitinen T, Manninen H, Niemi P, Peuhkurinen K, Jaaskelainen P, et al. Radiology 2003 226 129 137 10.1148/radiol.2261011874 12511681 (Pubitemid 36163920)
78. Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study. Knaapen P, van Dockum WG, Gotte MJ, Broeze KA, Kuijer JP, Zwanenburg JJ, Marcus JT, Kok WE, van Rossum AC, Lammertsma AA, Visser FC, J Nucl Cardiol 2006 13 660 667 10.1016/j.nuclcard.2006.05.018 16945746 (Pubitemid 44283785)
79. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA, Selvanayagam JB, Neubauer S, Watkins H, Circulation 2007 115 2418 2425 10.1161/CIRCULATIONAHA. 106.657023 17452610 (Pubitemid 46717964)
80. [What is late gadolinium enhancement in hypertrophic cardiomyopathy?]. Moon JC, Rev Esp Cardiol 2007 60 1 4 17352851 (Pubitemid 46359171)
81. Delayed hyper-enhancement of myocardium in hypertrophic cardiomyopathy with asymmetrical septal hypertrophy: comparison with global and regional cardiac MR imaging appearances. Amano Y, Takayama M, Takahama K, Kumazaki T, J Magn Reson Imaging 2004 20 595 600 10.1002/jmri.20172 15390225 (Pubitemid 39313735)
82. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Teraoka K, Hirano M, Ookubo H, Sasaki K, Katsuyama H, Amino M, Abe Y, Yamashina A, Magn Reson Imaging 2004 22 155 161 10.1016/j.mri.2003.08.009 15010107 (Pubitemid 38326634)
83. Original report. Late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging. Bogaert J, Goldstein M, Tannouri F, Golzarian J, Dymarkowski S, AJR Am J Roentgenol 2003 180 981 985 12646440 (Pubitemid 36363036)
84. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ, Circ Heart Fail 2008 1 184 191 10.1161/CIRCHEARTFAILURE.108.768119 19808288
85. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Moon JC, Mogensen J, Elliott PM, Smith GC, Elkington AG, Prasad SK, Pennell DJ, McKenna WJ, Heart 2005 91 1036 1040 10.1136/hrt.2004.041384 16020591 (Pubitemid 41060010)
86. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM, Eur Heart J 2003 24 2151 2155 10.1016/j.ehj.2003.09.017 14643276 (Pubitemid 37486535)
87. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ, J Cardiovasc Magn Reson 2006 8 479 482 10.1080/10976640600605002 16755835
88. Kaldoudi E, Williams CR, Relaxation time measurements in NMR imaging 1993
89. Tumor detection by nuclear magnetic resonance. Damadian R, Science 1971 171 1151 1153 10.1126/science.171.3976.1151 5544870
90. Myocardial T1 mapping for detection of left ventricular myocardial fibrosis in chronic aortic regurgitation: pilot study. Sparrow P, Messroghli DR, Reid S, Ridgway JP, Bainbridge G, Sivananthan MU, AJR Am J Roentgenol 2006 187 630 635 10.2214/AJR.05.1264 17114517
91. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ, J Am Coll Cardiol 2008 52 1574 1580 10.1016/j.jacc.2008.06.049 19007595
92. Contrast-enhanced myocardial T1-weighted scout (Look-Locker) imaging for the detection of myocardial damages in hypertrophic cardiomyopathy. Amano Y, Takayama M, Kumita S, J Magn Reson Imaging 2009 30 778 784 10.1002/jmri.21921 19787718
93. Abnormalities in T2-weighted cardiovascular magnetic resonance images of hypertrophic cardiomyopathy: regional distribution and relation to late gadolinium enhancement and severity of hypertrophy. Abdel-Aty H, Cocker M, Strohm O, Filipchuk N, Friedrich MG, J Magn Reson Imaging 2008 28 242 245 10.1002/jmri.21381 18581348 (Pubitemid 351956489)
94. Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. Schwartzkopff B, Mundhenke M, Strauer BE, J Am Coll Cardiol 1998 31 1089 1096 10.1016/S0735-1097(98)00036-9 9562012 (Pubitemid 28212511)
95. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG, N Engl J Med 2003 349 1027 1035 10.1056/NEJMoa025050 12968086 (Pubitemid 37087617)
96. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Abdel-Aty H, Zagrosek A, Schulz-Menger J, Taylor AJ, Messroghli D, Kumar A, Gross M, Dietz R, Friedrich MG, Circulation 2004 109 2411 2416 10.1161/01.CIR.0000127428.10985.C6 15123531 (Pubitemid 38679560)
97. Diffusion MR tractography of the heart. Sosnovik DE, Wang R, Dai G, Reese TG, Wedeen VJ, J Cardiovasc Magn Reson 2009 11 47 10.1186/1532-429X-11-47 19912654
98. Combined diffusion and strain MRI reveals structure and function of human myocardial laminar sheets in vivo. Dou J, Tseng WY, Reese TG, Wedeen VJ, Magn Reson Med 2003 50 107 113 10.1002/mrm.10482 12815685 (Pubitemid 36841866)
99. Imaging myocardial fiber disarray and intramural strain hypokinesis in hypertrophic cardiomyopathy with MRI. Tseng WY, Dou J, Reese TG, Wedeen VJ, J Magn Reson Imaging 2006 23 1 8 10.1002/jmri.20473 16331592 (Pubitemid 43100711)
100. Enhanced transmural fiber rotation and connexin 43 heterogeneity are associated with an increased upper limit of vulnerability in a transgenic rabbit model of human hypertrophic cardiomyopathy. Ripplinger CM, Li W, Hadley J, Chen J, Rothenberg F, Lombardi R, Wickline SA, Marian AJ, Efimov IR, Circ Res 2007 101 1049 1057 10.1161/CIRCRESAHA.107.161240 17885214 (Pubitemid 350084982)
101. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy. de Roos A, Doornbos J, Luyten PR, Oosterwaal LJ, van der Wall EE, den Hollander JA, J Magn Reson Imaging 1992 2 711 719 10.1002/jmri.1880020616 1446116
102. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Jung WI, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O, Bunse M, van Erckelens F, Apitz J, Lutz O, Dietze GJ, Circulation 1998 97 2536 2542 9657474 (Pubitemid 28294500)
103. (31)P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: Experiences at 3T. Shivu GN, Abozguia K, Phan TT, Ahmed I, Henning A, Frenneaux M, Eur J Radiol 2010 73 255 259 10.1016/j.ejrad.2008.10.018 19056193
104. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, et al. Circulation 2010 122 1562 1569 10.1161/CIRCULATIONAHA.109. 934059 20921440
105. Sudden death in young athletes. Maron BJ, N Engl J Med 2003 349 1064 1075 10.1056/NEJMra022783 12968091 (Pubitemid 37098275)
106. Ventricular septal crypt in hypertrophic cardiomyopathy. Maron BJ, Lindberg J, Lesser JR, Eur Heart J 2010 31 1923 10.1093/eurheartj/ehq140 20501477
107. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. Tadamura E, Yamamuro M, Kubo S, Kanao S, Saga T, Harada M, Ohba M, Hosokawa R, Kimura T, Kita T, Togashi K, AJR Am J Roentgenol 2005 185 110 115 15972409
108. Images in cardiovascular medicine. Diagnostic utility of cardiac magnetic resonance imaging in monozygotic twins with hypertrophic cardiomyopathy and identical pattern of left ventricular hypertrophy. Maron BJ, Haas TS, Lesser JR, Circulation 2007 115 627 628 10.1161/CIRCULATIONAHA.106.680512 17576874 (Pubitemid 46956504)
109. Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging. Pons-Llado G, Carreras F, Borras X, Palmer J, Llauger J, Bayes de Luna A, Am J Cardiol 1997 79 1651 1656 10.1016/S0002-9149(97)00216-6 9202357 (Pubitemid 27339476)
110. Assessment of quantitative hypertrophy scores in hypertrophic cardiomyopathy: magnetic resonance imaging versus echocardiography. Posma JL, Blanksma PK, van der Wall EE, Hamer HP, Mooyaart EL, Lie KI, Am Heart J 1996 132 1020 1027 10.1016/S0002-8703(96)90016-2 8892778 (Pubitemid 26372762)
111. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ, Circ Heart Fail 3 51 58
112. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Kwon DH, Setser RM, Popovic ZB, Thamilarasan M, Sola S, Schoenhagen P, Garcia MJ, Flamm SD, Lever HM, Desai MY, Int J Cardiovasc Imaging 2008 24 617 625 10.1007/s10554-008-9292-6 18204915
113. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications. Paya E, Marin F, Gonzalez J, Gimeno JR, Feliu E, Romero A, Ruiz-Espejo F, Roldan V, Climent V, de la Morena G, Valdes M, J Card Fail 2008 14 414 419 10.1016/j.cardfail.2008. 02.006 18514934 (Pubitemid 351749840)
114. Cardiovascular magnetic resonance signs of ischemia in hypertrophic cardiomyopathy. Melacini P, Corbetti F, Calore C, Pescatore V, Smaniotto G, Pavei A, Bobbo F, Cacciavillani L, Iliceto S, Int J Cardiol 2008 128 364 373 10.1016/j.ijcard.2007.06.023 17643520
115. Delayed enhancement in hypertrophic cardiomyopathy: comparison with myocardial tagging MRI. Kim YJ, Choi BW, Hur J, Lee HJ, Seo JS, Kim TH, Choe KO, Ha JW, J Magn Reson Imaging 2008 27 1054 1060 10.1002/jmri.21366 18425835 (Pubitemid 351614616)
116. Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis. Debl K, Djavidani B, Buchner S, Lipke C, Nitz W, Feuerbach S, Riegger G, Luchner A, Heart 2006 92 1447 1451 10.1136/hrt.2005.079392 16606864 (Pubitemid 44578839)
117. Magnetic resonance imaging of delayed enhancement in hypertrophic cardiomyopathy: relationship with left ventricular perfusion and contractile function. Soler R, Rodriguez E, Monserrat L, Mendez C, Martinez C, J Comput Assist Tomogr 2006 30 412 420 10.1097/00004728-200605000-00011 16778615 (Pubitemid 43922258)
118. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H, J Am Coll Cardiol 56 875 887
119. Myocardial scar detected by contrast-enhanced cardiac magnetic resonance imaging is associated with ventricular tachycardia in hypertrophic cardiomyopathy patients. Suk T, Edwards C, Hart H, Christiansen JP, Heart Lung Circ 2008 17 370 374 10.1016/j.hlc.2008.03.080 18562248